EC Number   |
Application |
Reference |
|---|
    3.1.1.4 | analysis |
development of a spectrophotometric assay to measure, continuously and specifically, phospholipase A1 or phospholipase A2 activities using synthetic glycerophosphatidylcholines containing alpha-eleostearic acid. Substrates 1-alpha-eleostearoyl-2-octadecyl-rac-glycero-3-phosphocholine or 1-octadecyl-2-alpha-eleostearoyl-rac-glycero-3-phosphocholine differentiate, with excellent accuracy, between PLA1 and PLA2 activity |
751273 |
| 3.1.1.4 | analysis |
simple and inexpensive protein expression, refolding and purification system may be useful for site-directed mutagenesis experiments of sPLA2-IID which will advance the understanding of the structurefunction relationship and biological effects of the protein |
710476 |
| 3.1.1.4 | biotechnology |
the enzyme is active and stable at higher temperatures, which suggests its great potential in biotechnological applications |
750890 |
| 3.1.1.4 | drug development |
applicability of minocycline as a lead compound for the design of specific inhibitors of PLA2, which play a crucial role in inflammatory processes |
709545 |
| 3.1.1.4 | drug development |
capacity of the cPLA2-alpha inhibitors to block or reduce simultaneously the production of the two major classes of lipid mediators, eicosanoids and platelet activating factor, potentially endows these molecules with a very potent anti-inflammatory activity. The cPLA2-alpha inhibitors AZ-1 and pyrrolidine-1 are effective at submicromolar concentrations when macrophages are stimulated by physiological agonists (Mycobacterium tuberculosis purified protein derivative and lipopolysaccharide) provides a rationale for the use of these inhibitors in the treatment of inflammatory lung diseases |
707554 |
| 3.1.1.4 | drug development |
design of new analogues with enhanced binding energy in the GIIA sPLA2 active site by systematic modifications of the pharmacophore segments of the FPL67047XX inhibitor |
709282 |
| 3.1.1.4 | drug development |
development of Lp-PLA2 inhibitors as therapy for atherosclerosis |
680922 |
| 3.1.1.4 | drug development |
herbal compounds (acalyphin, chlorogenic acid, stigmasterol, curcumin and tectoridin) and marine compounds (gracilin A and aplysulphurin A) show favorable interactions with the amino acid residues at the active site of PLA2, thereby substantiating their proven efficacy as anti-inflammatory compounds and antidotes |
708701 |
| 3.1.1.4 | drug development |
influence on regulation of sPLA2(IIA) activity can be useful in the development of new therapeutic approaches to the treatment of cardiovascular diseases |
710455 |
| 3.1.1.4 | drug development |
inhibition of iPLA2 and lysophospholipid production may be of interest to reduce Ca2+ entry and subsequent degeneration of dystrophic muscle |
707389 |
